KIORA PHARMACEUTICALS, INC.

Consensus Kiora Pharmaceuticals, Inc.

Stocks

KPRX

US49721T5074

Biotechnology & Medical Research

Market Closed - Nasdaq 16:30:00 2026-10-28 EDT			5-day change	1st Jan Change
2.360 ^USD	+2.61%		+0.85%	+19.80%

09-08	Kiora Pharmaceuticals, Inc. Appoints Keith Lane as Executive Vice President, Head of Clinical Development and Regulatory Affairs, Effective September 1, 2026	CI
08-19	Kiora Pharmaceuticals, Inc. Licenses South Korean Ophthalmic Development And Commercialization Rights For KIO-301 To Chong Kun Dang Pharmaceutical Corporation	CI

Evolution of the Average Target: Kiora Pharmaceuticals, Inc.

Evolution of the Average Target - Kiora Pharmaceuticals, Inc.

Evolution of the Target Price: Kiora Pharmaceuticals, Inc.

Evolution of the Target Price - Kiora Pharmaceuticals, Inc.

Changes in Analyst Recommendations: Kiora Pharmaceuticals, Inc.

97f6a8ee0f5b007e6bd5fca4478c.u561YuXhYFr8T-xb-A7hrftwZrHntjtFvmUHjAafJpc.0qnZJtK3BgWdKZQar2CO6J4nJcK_w1QC-idKuFfrRdnWqOEyiqpWNqsdjw~51d7e17d0e2c983280da4147436b7910

Analysts' recommendations: Kiora Pharmaceuticals, Inc.

24-02-09	HC Wainwright Adjusts Price Target on Kiora Pharmaceuticals to $2 From $3.50, Maintains Buy Rating	MT
23-11-06	HC Wainwright Adjusts Kiora Pharmaceuticals' Price Target to $3.50 From $2, Keeps Buy Rating	MT
23-08-14	HC Wainwright Adjusts Price Target on Kiora Pharmaceuticals to $2 From $7, Keeps Buy Rating	MT
23-05-12	HC Wainwright Raises Kiora Pharmaceuticals' Price Target to $7 From $6, Maintains Buy Rating	MT
23-02-09	Maxim Upgrades Kiora Pharmaceuticals to Buy From Hold, Price Target is $12	MT
23-02-08	Ladenburg Thalmann Reiterates Kiora Pharmaceuticals at Buy With $119 Price Target	MT
23-02-08	HC Wainwright Reiterates Kiora Pharmaceuticals at Buy With $10 Price Target	MT
22-08-25	Ladenburg Thalmann Initiates Kiora Pharmaceuticals at Buy With $6.50 Price Target	MT
22-08-15	Maxim Group Downgrades Kiora Pharmaceuticals to Hold From Buy	MT
22-07-11	HC Wainwright Adjusts Price Target on Kiora Pharmaceuticals to $2.50 From $3, Reiterates Buy Rating	MT
22-04-19	HC Wainwright Adjusts Kiora Pharmaceuticals Price Target to $3 From $5, Maintains Buy Rating	MT
22-01-19	Maxim Starts Kiora Pharmaceuticals at Buy With $2.50 Price Target	MT
21-08-16	EyeGate Pharmaceuticals : HC Wainwright Adjusts Price Target on Eyegate Pharmaceuticals to $11 From $14, Maintains Buy Rating	MT
21-05-18	EyeGate Pharmaceuticals : Alliance Global Securities Adjusts Eyegate Pharmaceuticals PT to $10.75 From $10.25, Maintains Buy Rating	MT
21-03-31	EyeGate Pharmaceuticals : Alliance Global Partners Adjusts Eyegate Pharmaceuticals PT $10.25 From $16.75, Maintains Buy Rating	MT
20-12-22	EyeGate Pharmaceuticals : HC Wainwright Adjusts Eyegate Pharmaceuticals' Price Target to $14 From $10, Keeps at Buy	MT
20-12-22	EyeGate Pharmaceuticals : Alliance Global Partners Adjusts Eyegate Pharmaceuticals PT to $15.50 From $9.50, Maintains Buy Rating	MT
20-11-12	EyeGate Pharmaceuticals : HC Wainwright Adjusts Eyegate Pharmaceuticals' Price Target to $10 From $12, Keeps Buy Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	KIORA PHARMACEUTICALS, INC.			-	-	+421.74%
	WUXI APPTEC CO., LTD.					+41.32%
	ARGENX SE					+28.63%
	LONZA GROUP AG					+9.56%
	IQVIA HOLDINGS INC.					+12.15%
	BEONE MEDICINES AG					+19.23%
	REVOLUTION MEDICINES, INC.					+39%
	CELLTRION, INC.					+42.31%
	GENMAB A/S					+6.5%
	WUXI BIOLOGICS (CAYMAN) INC.					+35.02%
	Average					+65.55%
	Weighted average by Cap.					+26.21%

See all sector performances

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

OUTPERFORM

Number of Analysts

1

Last Close Price

2.360USD

Average target price

12.00USD

Spread / Average Target

+408.47%

High Price Target

12.00USD

Spread / Highest target

+408.47%

Low Price Target

12.00USD

Spread / Lowest Target

+408.47%

Analyst Consensus Detail

Analyst consensus - Kiora Pharmaceuticals, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Kiora Pharmaceuticals, Inc.

Stock Market
Stocks
KPRX Stock
Consensus Kiora Pharmaceuticals, Inc.

As early as today, start finding the best investment opportunities!

×